<DOC>
	<DOCNO>NCT00414687</DOCNO>
	<brief_summary>The purpose study determine whether study drug effective long-term treatment primary secondary pulmonary hypertension</brief_summary>
	<brief_title>Aerosolized Randomized Iloprost Study II ( AIR - II ) Long-Term Safety , Tolerability , Clinical Effects Iloprost Inhalation Patients With Primary Secondary Pulmonary Hypertension</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer Schering Pharma AG , Germany . Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>Male female patient Secondary pulmonary hypertension Mean pulmonary artery pressure equal 40 mmHg primary pulmonary hypertension pressure equal 30 mmHg rest appropriate conventional treatment Written inform consent duly inform diagnostic therapeutic measure involve study Clinical Instability baseline Pulmonary venous obstruction Global respiratory insufficiency Obstructive ventilation disorder , Interstitial pulmonary disease Cerebrovascular event Myocardial infarction major cardiac surgery within 3 month prior baseline Bleeding disorder bleed risk Severe hepatic insufficiency renal insufficiency Malignant diseases HIV positive Pregnancy , female patient childbearing potential without adequate contraception nursing mother Congenital acquire valvular defect myocardial function disorder related pulmonary hypertension Prior pulmonary embolism Collagenosis Pulmonary arterial valvular stenosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Primary secondary Pulmonary hypertension</keyword>
	<keyword>Iloprost</keyword>
	<keyword>Inhaled</keyword>
	<keyword>Long-term treatment</keyword>
</DOC>